{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mineharu Y"],"funding":["NINDS NIH HHS"],"pagination":["827-43"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3480576"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(4)"],"pubmed_abstract":["Immune-mediated gene therapy using adenovirus expressing Flt3 ligand and thymidine kinase followed by ganciclovir administration (Flt3/TK) effectively elicits tumor regression in preclinical glioma models. Herein, we assessed new strategies to optimize Flt3L/TK therapeutic efficacy in a refractory RG2 orthotopic glioblastoma model. Specifically, we aimed to optimize the therapeutic efficacy of Flt3L/TK treatment in the RG2 model by overexpressing the following genes within the brain tumor microenvironment: 1) a TK mutant with enhanced cytotoxicity (SR39 mutant TK), 2) Flt3L-IgG fusion protein that has a longer half-life, 3) CD40L to stimulate DC maturation, 4) T helper cell type 1 polarizing dendritic cell cytokines interleukin-12 or C-X-C motif ligand 10 chemokine (CXCL)-10, 5) C-C motif "],"journal":["Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"],"pubmed_title":["Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model."],"pmcid":["PMC3480576"],"funding_grant_id":["R01 NS061107","UO1-NS052465-04S1","R01 NS057711","F32 NS058156","1UO1 NS052465","1R01-NS074387","U01 NS052465","1R01-NS061107","1R01-NS054193","1R01-NS057711","R01 NS074387","1F32 NS058156","R01 NS054193"],"pubmed_authors":["Puntel M","Allison JP","Muhammad AK","Candolfi M","Lugo C","Mineharu Y","Castro MG","Xiong W","Yagiz K","Levy E","Kroeger KM","Liu C","Lowenstein PR","Kocharian A","Curran MA"],"additional_accession":[]},"is_claimable":false,"name":"Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.","description":"Immune-mediated gene therapy using adenovirus expressing Flt3 ligand and thymidine kinase followed by ganciclovir administration (Flt3/TK) effectively elicits tumor regression in preclinical glioma models. Herein, we assessed new strategies to optimize Flt3L/TK therapeutic efficacy in a refractory RG2 orthotopic glioblastoma model. Specifically, we aimed to optimize the therapeutic efficacy of Flt3L/TK treatment in the RG2 model by overexpressing the following genes within the brain tumor microenvironment: 1) a TK mutant with enhanced cytotoxicity (SR39 mutant TK), 2) Flt3L-IgG fusion protein that has a longer half-life, 3) CD40L to stimulate DC maturation, 4) T helper cell type 1 polarizing dendritic cell cytokines interleukin-12 or C-X-C motif ligand 10 chemokine (CXCL)-10, 5) C-C motif ","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Oct","modification":"2025-07-09T03:04:58.432Z","creation":"2025-07-09T03:04:58.432Z"},"accession":"S-EPMC3480576","cross_references":{"pubmed":["22996231"],"doi":["10.1007/s13311-012-0144-7"]}}